Benefits and Harms of Prescription Drugs and Supplements for Treatment of Clinical Alzheimer-Type Dementia

@article{Fink2020BenefitsAH,
  title={Benefits and Harms of Prescription Drugs and Supplements for Treatment of Clinical Alzheimer-Type Dementia},
  author={Howard A Fink and Eric J. Linskens and Roderick MacDonald and Pombie C Silverman and John Riley McCarten and Kristine M. C. Talley and Mary L. Forte and Priyanka Desai and Victoria A. Nelson and Margaret A. Miller and Laura Sue Hemmy and Michelle Brasure and Brent C. Taylor and Weiwen Ng and Jeannine M Ouellette and Kerry M Sheets and Timothy J. Wilt and Mary E Butler},
  journal={Annals of Internal Medicine},
  year={2020},
  volume={172},
  pages={656 - 668}
}
Background Effects of drug treatment of clinical Alzheimer-type dementia (CATD) are uncertain. Purpose To summarize evidence on the effects of prescription drugs and supplements for CATD treatment. Data Sources Electronic bibliographic databases (inception to November 2019), ClinicalTrials.gov (to November 2019), and systematic review bibliographies. Study Selection English-language trials of prescription drug and supplement treatment in older adults with CATD that report cognition… 
Optimizing the diagnosis and management of dementia within primary care: a systematic review of systematic reviews
TLDR
The findings from this systematic review will inform family physicians on how to improve dementia diagnosis and management within their primary care practice.
Potentially Inappropriate Prescriptions of Antipsychotics for Patients With Dementia
TLDR
Increased age, being treated with memantine, simultaneously presenting with anxiety, depression, and psychotic disorders, and concomitantly receiving anticonvulsants, bronchodilators and benzodiazepines were associated with a greater probability of being prescribed antipsychotics.
Discontinued disease-modifying therapies for Alzheimer’s disease: status and future perspectives
TLDR
Key drugs that have been discontinued while in development for AD are reviewed and the future landscape for present and alternative approaches are delineated, including apolipoprotein E, immunomodulation, plasma exchange, protein autophagy and clearance, mitochondrial dysfunction, abnormal glucose metabolism and neurovascular unit support.
Priorities and Preferences of People Living with Dementia or Cognitive Impairment – A Systematic Review
TLDR
A systematic review of studies about patient preferences provides essential insights into cognitively impaired patients’ preferences, which are rarely considered in treatment, care, and support services.
Alzheimer Disease Clinical Trials Targeting Amyloid
TLDR
The natural progression of AD is considered and how it continues despite present attempts to modify the amyloid-related machinery to alter the disease trajectory, which may prove crucial for the leap forward toward novel therapeutic targets to treat AD.
Trends in Dementia and Mild Cognitive Impairment Prevalence and Incidence in German General and Specialist Practices Between 2015 and 2019.
TLDR
The results confirmed the reduction in the prevalence and incidence of dementia and revealed a decrease in the number of patients with dementia despite continued demographic changes.
Associations Between Oral Health Status, Perceived Stress, and Neuropsychiatric Symptoms Among Community Individuals With Alzheimer's Disease: A Mediation Analysis
TLDR
Direct and indirect associations linking oral health-related stressors and PS with NPS in individuals with AD are identified and suggest that targeted dental care and oral- related stressor control may be valuable for managing NPS.
Mindfulness-Based Training Does Not Improve Neuropsychological Outcomes in Mild Cognitive Impairment More Than Spontaneous Reversion Rates: A Randomized Controlled Trial.
TLDR
The results suggest that a cognition-focused MBT did not improve cognitive functioning in MCI patients substantially more than spontaneous reversion rates, possibly as mood symptoms were not significantly alleviated in this group.
Effects of New Galantamine Derivatives in a Scopolamine Model of Dementia in Mice.
TLDR
Four newly synthesized galantamine derivatives were evaluated for a beneficial effect in a scopolamine model of dementia in mice, showing that Gal 43, Gal 44, and Gal 46 are especially effective in improving both short- and long-term memory and in the case of Gal 46 having a significant effect on exploratory activity as well.
...
1
2
...

References

SHOWING 1-10 OF 105 REFERENCES
Systematic Review of Measures of Clinical Significance Employed in Randomized Controlled Trials of Drugs for Dementia
TLDR
A systematic review was performed of double‐blind randomized controlled trials (RCTs) of cholinesterase inhibitors and memantine in subjects with Alzheimer's disease, vascular dementia, mixed dementia, and mild cognitive impairment to better understand what measures of clinical significance have been employed in dementia drug research.
Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline
TLDR
This systematic review systematically evaluates the evidence for the effectiveness of these 5 drugs in improving outcomes in cognition, global function, behavior, and quality of life among patients with dementia.
Effect of memantine combined with citalopram on cognition of BPSD and moderate Alzheimer's disease: A clinical trial
TLDR
Memantine combined with citalopram can more effectively improve the cognitive function, and reduce behavioral and psychological symptoms in patients with moderate AD, and has shown potential efficacy in adjunctive therapy of AD patients with BPSD.
Aripiprazole for the Treatment of Psychosis in Patients With Alzheimer's Disease: A Randomized, Placebo-Controlled Study
TLDR
Aripiprazole showed similar improvements to placebo in psychotic symptoms as assessed by NPI Psychosis subscale scores, but significantly greater effects on BPRS Core and Psychosis assessments in community-living AD patients with psychosis.
Pimavanserin in Alzheimer’s Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms
TLDR
Pimavanserin demonstrated significant efficacy in AD psychosis in patients with higher baseline severity of psychotic symptoms (NPI-NH-PS ≥12), and treatment with pimavANSerin showed an acceptable tolerability profile.
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
TLDR
The data indicate that donepezil is a well-tolerated drug that improves cognition and global function in patients with mild to moderate AD.
Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial.
  • E. Peskind, S. Potkin, S. McDonald
  • Psychology, Medicine
    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry
  • 2006
OBJECTIVE The objective of this study was to compare the efficacy and safety of the moderate-affinity, uncompetitive N-methyl-d-aspartate receptor antagonist, memantine, versus placebo in patients
...
1
2
3
4
5
...